Petefészekrák: vizsgálatok itt: Ausztrália
59 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Clayton, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Adelaide, Auchenflower, Clayton, Geelong, Hobart, Kogarah, Melbourne, Richmond, Subiaco, Sydney
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00 - 1. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Blacktown, Clayton, Melbourne
- Életkor
- 18 év and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - 1/2. fázisTaking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- East Melbourne
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - 1. fázisTaking peopleStudy of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Where
- Camperdown, Heidelberg, Melbourne, Waratah
- Életkor
- 18 év and over
- People
- 473 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT04429542 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Darlinghurst, Melbourne, Randwick
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Liverpool, Melbourne
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Bedford Park, Camperdown, Clayton, Nedlands, South Brisbane
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Where
- Newcastle
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07684612 · EU 2025-523366-24-00 - 1/2. fázisTaking peopleStudy of AVZO-021 in Patients With Advanced Solid Tumors
- Where
- Macquarie University, Wollongong
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Avenzo Therapeutics, Inc.
See details and how to joinNCT05867251 - 1/2. fázisBefejeződöttStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Melbourne, Randwick
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 1/2. fázisTaking peopleEvaluation of XYA02 in Patients With Advanced Solid Tumors
- Where
- Melbourne, Perth, Sydney
- Életkor
- 18 év and over
- People
- 190
- Run by
- XYone Therapeutics, Inc
See details and how to joinNCT07670312 - 1. fázisTaking peopleA Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Where
- Adelaide, Brisbane, Camperdown, Geelong, Sydney
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Kivu Bioscience Inc.
See details and how to joinNCT07229313 - 2. fázisTaking peopleA Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Adelaide, Blacktown, Concord, Hobart
- Életkor
- 18 év to 99 év
- People
- 160 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07023627 · EU 2025-521513-14-00 - 1/2. fázisTaking peopleSL-28 for Advanced Solid Tumours
- Where
- Adelaide, Gold Coast, Sydney
- Életkor
- 18 év and over
- People
- 60
- Run by
- Second Life Therapeutics
See details and how to joinNCT07341737 - 3. fázisTaking peopleActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Where
- Clayton, Hunter Regional Mail Centre, Parkville, Perth, Randwick, South Brisbane, Westmead
- People
- 1780 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT03067181 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Southport, Waratah
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - 1/2. fázisTaking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Blacktown, Brisbane, Liverpool, Malvern, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - 1/2. fázisTaking peopleA Study of DM002 in Patients With Advanced Solid Tumors
- Where
- Adelaide, Randwick, Wollongong
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
See details and how to joinNCT06751329 - 1. fázisTaking peopleIDOV-Immune for Advanced Solid Tumors
- Where
- Melbourne, Westmead
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- ViroMissile, Inc.
See details and how to joinNCT06910657 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Bedford Park, Melbourne, New Lambton Heights, Orange, Randwick
- Életkor
- 8 év and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Adelaide, Auchenflower, Campbelltown, Camperdown, Clayton, Cudgen, Garran, Gosford, Heidelberg, Kogarah, Melbourne, Richmond, St Leonards, Waratah
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - 1. fázisTaking peopleA First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Where
- Aberfoyle Park, South Brisbane
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Stemline Therapeutics, Inc.
See details and how to joinNCT07226427 · EU 2025-524168-39-00 - 1. fázisTaking peopleA Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- Where
- Adelaide, Ryde, Sydney, Westmead
- Életkor
- 18 év and over
- People
- 36
- Run by
- EtiraRx Australia Pty Ltd
See details and how to joinNCT06533332 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Where
- Ballarat, Blacktown, Brisbane, Chermside, Clayton, Lambton Heights, Nedlands
- Életkor
- 18 év and over
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT06682988 · EU 2024-517184-23-00